Implementation of an antenatal magnesium sulfate protocol for fetal neuroprotection in preterm infants.
Implementation of an antenatal magnesium sulfate protocol for fetal neuroprotection in preterm infants.
复制标题
DOI：
10.1038/srep14732
复制
发表时间：
2015-09-29
影响因子：
4.6
通讯作者：
Sentilhes L
中科院分区：
文献类型：
--
作者：
Bouet PE;Brun S;Madar H;Baisson AL;Courtay V;Gascoin-Lachambre G;Lasocki S;Sentilhes L
本研究的目的是评估实施硫酸镁预防脑瘫方案的可行性。本回顾性单中心研究纳入2011年9月至2012年12月24小时内计划或预期分娩的所有胎龄<33周的妇女。他们接受硫酸镁的静脉注射，每次4克，然后每小时持续输注1克。如果12小时后仍未分娩，且不再认为即将分娩，则应停止输注。该研究包括119名妇女，其中81名（68.1%）接受硫酸镁治疗。其中71例（87.5%）在24小时内分娩。未给予治疗的原因为：医疗团队疏漏（19/ 38,50%）、紧急分娩（18/ 38,47.4%）和治疗禁忌症（1/ 38,2.6%）。方案实施时的平均胎龄为29.6±2.1周。产妇监测，特别是在输液开始时，似乎不太理想。没有观察到主要的母体副作用。我们的研究表明，在三级产科中心实施硫酸镁预防脑瘫的方案是可行的。
The aim of our study was to assess the feasibility of implementing a protocol for the use of magnesium sulfate to prevent cerebral palsy. This retrospective single-center study included all women with fetuses of gestational age <33 weeks of gestation whose birth was planned or expected within 24 hours from September 2011 to December 2012. They were to receive magnesium sulfate, administered intravenously as a 4-g bolus followed by a constant infusion of 1 g per hour. If delivery had not occurred after 12 hours and was no longer considered imminent, the infusion was to be discontinued. The study included 119 women, 81 (68.1%) of whom received magnesium sulfate. Among the latter, 71 (87.5%) gave birth within 24 hours. The reasons treatment was not given were: omission by medical team (19/38, 50%), urgent delivery (18/38, 47.4%), and contraindication to treatment (1/38, 2.6%). The mean gestational age at protocol implementation was 29.6 +/− 2.1 weeks. Maternal monitoring, especially at the onset of infusion, appeared suboptimal. No major maternal side effects were observed. Our study shows that implementing a protocol for prevention of cerebral palsy by magnesium sulfate is feasible in a tertiary obstetric center.